Trial Profile
High Dose Icotinib in Advanced Non-small Cell Lung Cancer With EGFR 21 Exon Mutation (INCREASE): a Randomized, Open-label Study
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Icotinib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms INCREASE
- Sponsors Betta Pharmaceuticals Co Ltd
- 14 Feb 2020 Results (at data cut-off: 15 May 2019; n=194) in the modified intention to treat population assessing progression free survival in non small cell lung cancer patients, published in the Clinical Cancer Research.
- 26 Sep 2018 Results (n=253) presented at the 19th World Conference on Lung Cancer
- 27 Jul 2017 Status changed from active, no longer recruiting to recruiting.